Moscone Center, San Francisco, CA
Two posters presenting preclinical data on lirilumab in combination with elotuzumab in mouse models of multiple myeloma will be presented at the upcoming 56th ASH Annual Meeting.
- “Lirilumab Enhances Anti-Tumor Efficacy of Elotuzumab” Publication Number: 4711
- “Effects of IL-21, KIR Blockade, and CD137 Agonism on the Non-Clinical Activity of Elotuzumab” Publication Number: 4717
Both posters will be presented at the same session:
Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III
Date: Monday, December 8, 2014
Presentation Time: 6:00 PM - 8:00 PM
Location: Moscone Center, West Building, Level 1
Posters will be available here at their public presentation.
Date